Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
6.38
-0.20 (-3.04%)
Nov 10, 2025, 3:48 PM EST - Market open
Silence Therapeutics Revenue
Silence Therapeutics had revenue of $159.00K in the quarter ending September 30, 2025, a decrease of -89.61%. This brings the company's revenue in the last twelve months to $25.83M, up 18.63% year-over-year. In the year 2024, Silence Therapeutics had annual revenue of $43.26M with 36.71% growth.
Revenue (ttm)
$25.83M
Revenue Growth
+18.63%
P/S Ratio
12.03
Revenue / Employee
$222,672
Employees
116
Market Cap
301.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43.26M | 11.62M | 36.71% |
| Dec 31, 2023 | 31.64M | 9.99M | 46.12% |
| Dec 31, 2022 | 21.66M | 4.84M | 28.82% |
| Dec 31, 2021 | 16.81M | 9.33M | 124.73% |
| Dec 31, 2020 | 7.48M | 7.16M | 2,214.81% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SLN News
- 4 days ago - Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 18 days ago - Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) - Business Wire
- 2 months ago - Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Silence Therapeutics to Participate in September Investor Conferences - Business Wire
- 3 months ago - Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 5 months ago - Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera - Business Wire
- 6 months ago - Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 6 months ago - Silence Therapeutics Welcomes Tim McInerney to Board of Directors - Business Wire